Probiotics for the Prevention of Clostridioides difficile–Associated Diarrhea in Adults and Children

Francesca Cimino, MD, MPHE, FAAFP,
Department Chair and Associate Professor, Department of Family Medicine, Uniformed Services University, Bethesda, Maryland
Jeffrey C. Leggit, MD, CAQSM,
Professor, Department of Family Medicine, Uniformed Services University, Bethesda

American Family Physician. 2026;114(5):466-467.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

CLINICAL QUESTION

Are probiotics in conjunction with antibiotics safe and effective for reducing the risk of Clostridioides difficile–associated diarrhea?

EVIDENCE-BASED ANSWER

Using probiotics in conjunction with antibiotics is safe and effective for reducing the incidence of C difficile–associated diarrhea.1 (Strength of Recommendation: B, inconsistent or low-quality patient-oriented evidence.)

PRACTICE POINTERS

Antibiotics can significantly affect the gut microbiome, resulting in diarrhea and other symptoms. C difficile infection is a form of antibiotic-associated diarrhea that can result in morbidity and mortality, including inflammation, toxic megacolon, and death. Probiotics are live microbial preparations that may promote gut microbiome restoration, which can theoretically prevent diarrhea. The authors of this Cochrane review sought to determine whether probiotics reduce the incidence of C difficile–associated diarrhea.2

This Cochrane review included 47 studies (N = 15,260), including eight new studies since the previous review in 2017.1,3 All studies were conducted in North America, Europe, and Asia. Age range was 4.5 to 78 years; eight studies included only children. Four studies recruited outpatients, six recruited inpatients and outpatients, and 37 recruited inpatients. All patients received an antibiotic to treat an infection, with an adjunctive probiotic to prevent C difficile–associated diarrhea. Any study that used probiotics for treatment rather than prevention of C difficile–associated diarrhea was excluded.

Not all studies had a published protocol or clinical trial registration. Inconsistencies in reported methods and published results reduced the overall quality of the evidence.1

Primary outcomes were reduction in cases of C difficile–associated diarrhea, C difficile colonization, adverse events, and antibiotic-associated diarrhea (ie, diarrhea occurring regardless of C difficile infection in patients recently treated with antibiotics).1 A secondary outcome, evaluated in seven trials (n = 6,553), was the length of hospitalization for those who required inpatient antibiotic treatment for the index infection.

Treatment duration ranged from 1 to 366 days (average = 7–14 days).1 The most common antibiotics prescribed were penicillins and cephalosporins. There was significant heterogeneity in the probiotic species used. The most common species were Saccharomyces boulardii, Lactobacillus rhamnosus, and Lactobacillus acidophilus plus Lacticaseibacillus casei. Some studies used two species, whereas others used three or more. The daily dosage of probiotics ranged from 100 million colony-forming units to 900 billion colony-forming units. The usual duration of probiotic use mirrored the antibiotic course but extended up to 1 week after antibiotic completion in some studies.

The evidence suggests that probiotics may be effective for preventing C difficile–associated diarrhea. Thirty-eight studies (n = 13,179) reported on the incidence of this condition.1 The absolute risk of C difficile–associated diarrhea decreased from 3.2% to 1.6% (absolute risk reduction = 1.6% [16 fewer cases per 1,000 patients treated]). This corresponds to a number needed to treat of approximately 63 (95% CI, 48–97).

Probiotics did not change the length of hospitalization (seven trials; n = 6,553).1 In subgroup analyses, there was no statistically significant difference in outcomes between adults and children. There was little to no difference in length of hospitalization between the intervention and control groups.

The apparent benefit of probiotics increased as the baseline risk of C difficile–associated diarrhea increased.1 In trials with low rates of C difficile–associated diarrhea at baseline (2% or less), probiotics produced little to no absolute benefit, whereas in moderate- and high-risk settings (eg, inpatient settings, outbreak scenarios with control event rates greater than 5%) probiotics were associated with progressively greater relative and absolute risk reductions. This pattern suggests that baseline risk (a proxy for clinical context and exposure intensity) is an important effect modifier and probiotics are more likely to be beneficial in higher-risk settings.

Author Disclosure: No relevant financial relationships.

  1. 1.Esmaeilinezhad Z, Ghosh NR, Walsh CM, et al. Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2025(9):CD006095.
  2. 2.Maftei NM, Raileanu CR, Balta AA, et al. The potential impact of probiotics on human health: an update on their health-promoting properties. Microorganisms. 2024;12(2):234.
  3. 3.Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017(12):CD006095.
  4. 4.Su GL, Ko CW, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697-705.

These are summaries of reviews from the Cochrane Library.

This series is coordinated by Corey D. Fogleman, MD, assistant medical editor.

A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.